Radiopharmaceuticals for imaging infection and inflammation

Abstract

The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

We claim:  
     
         1 . A reagent capable of direct transformation into a radiopharmaceutical having a binding affinity for the LTB4 receptor of less than 1000 nM.  
     
     
         2 . A reagent of  claim 1  having the formula: 
       W e —X—L n —Y—L n′ —C h , W e —X—L n (L n′ —C h )—Y, or Z—L n′ —C h , 
       wherein, 
 W e  is selected from the group:  
                     
 wherein,  
 A 1  is N, C—OH, or CH;  
 A 2  and A 3  are independently N or CH;  
 A 4  is N or CR 3 ;  
 A 5  is O or S;  
 A 6  is O, CH 2  or S;  
 A 7  is C—OH, N, NH, O or S;  
 A 8  is NH, CH 2 , O, S, N, or CH;  
 A 9  is N or CH;  
 a and b indicate the alternative positions of a double bond;  
 R 1  is selected from the group: H, —C(═NH)NH 2 , C 1 -C 6  alkyl substituted with 0-3 R 4 , C 1 -C 6  alkoxy substituted with 0-3 R 4 , aryl substituted with 0-3 R 5 , and heterocycle substituted with 0-3 R 5 ;  
 R 2  is selected from the group: H, C 1 -C 3  alkyl, C 2 -C 3  alkenyl, cyclopropyl, cyclopropylmethyl, and aryl substituted with 0-3 R 5 ;  
 R 3  is —H, —OH or C 1 -C 3  alkoxy;  
 or alternatively, R 1  and R 3  can be taken together with the atoms to which they are attached to form a fused phenyl ring substituted with 0-3 R 5 ;  
 R 4  is independently selected from the group: —F, —Cl, —Br, —I, ═O, —N(R 6 )(R 7 ), and —CF 3 ;  
 R 5  is independently selected from the group: —F, —Cl, —Br, —I, —N(R 6 )(R 7 ), —CF 3 , C 1 -C 3  alkyl, C 1 -C 3  alkoxy, and methylenedioxy;  
 R 6  and R 7  are independently H or C 1 -C 3  alkyl;  
 provided that when A 1  and A 2  are CH, A 3  is C—X, and A 4  is CR 3 , R 1  is selected from the group: 
 C 1 -C 5  alkyl substituted with 1-3 R 4 , C 1 -C 5  alkoxy substituted with 0-3 R 4 , and aryl substituted with, 0-3 R 5 ;  
 
 X is O, S, CH 2  or CH═CH;  
 L n  is a linking group having the formula 
 (CR 8 R 9 ) g —(W 1 ) h —(M 1 ) k —(CR 10 R 11 ) g′   
 wherein,  
 R 8 , R 9 , R 10  and R 11  are independently selected at each occurrence from the group: a bond to L n′ , H, C 1 -C 5  alkyl, and C 1 -C 5  alkoxy, or alternatively, R 8  and R 9  or R 10  and R 11  may be taken together to form a 3-6 membered cycloalkyl or heterocycle;  
 W 1  is independently selected from the group: O, S, C(═O)O, OC(═O), CH═CH, (OCH 2 CH 2 ) p  and (CH 2 CH 2 O) p′ , wherein p and p′ are independently 1-3;  
 M 1  is selected from the group: 
 phenyl substituted with 0-3 R 12 , heterocycle substituted with 0-3 R 12 , benzophenone substituted with 0-3 R 12 , and diphenylether substituted with 0-3 R 12 ;  
 
 R 12  is independently selected from the group: a bond to L n′ , —COOR 13 , C 1 -C 5  alkyl substituted with 0-3 R 14 , and C 1 -C 5  alkoxy substituted with 0-3 R 14 ;  
 R 13  is H or C 1 -C 5  alkyl:  
 R 14  is independently selected from the group: a bond to L n′ , and —COOH;  
 g is 0-10;  
 h is 0-3;  
 k is 0-1;  
 g′ is 0-5;  
 provided that when h is 0 and k is 0, g is >1;  
 and provided that when W 1  is O or S and k is 0, g+g′ is ≧1;  
 Y is selected from C(═O)NH, NHC(═O), C═O, C(═O)O, OC(═O), NHS(═O) 2 , C(═O)NHS(═O) 2 , COOH, C(═O)NH 2 , NH(C═O)NH, or tetrazole;  
 provided that from 0-1 of R 9 , R 10 , R 11 , R 12 , and R 14  is a bond to L n′  and when one of these variables is a bond to L n′ , then Y is COOH, C(═O)NH 2 , or tetrazole;  
 L n′  is a linking group having the formula: 
 (W 2 ) h′ —(CR 15 R 16 ) g″ —(M 2 ) k′ —(W 2 ) h″ —(CR 17 R 18 ) g″′ —(W 2 ) ′″   
 wherein,  
 W 2  is independently selected at each occurrence from the group: O, S, NH, NHC(═O), C(═O)NH, C(═O), C(═O)O, OC(═O), NHC(═O)NH, SO 2 , (OCH 2 CH 2 ) s , (CH 2 CH 2 O) s′ , (OCH 2 CH 2 CH 2 ) s″ , (CH 2 CH 2 CH 2 O) t , and (aa) t′ , wherein aa is independently at each occurrence an amino acid, and s, s′, s″, t, and t′ are independently 1-10;  
 M 2  is selected from the group: aryl substituted with 0-3 R 19 , cycloalkyl substituted with 0-3 R 19 , and heterocycle substituted with 0-3 R 19 ;  
 R 15 , R 16 , R 17  and R 18  are independently selected at each occurrence from the group: —O, COOH, SO 3 H, PO 3 H, C 1 -C 5  alkyl substituted with 0-3 R 19 , aryl substituted with 0-3 R 19 , benzyl substituted with 0-3 R 19 , and C 1 -C 5  alkoxy substituted with 0-3 R 19 , NHC(═O)R 20 , C(═O)NHR 20 , NHC(═O)NHR 20 , NHR 20 , R 20 , and a bond to C h ;  
 R 19  is independently selected at each occurrence from the group: COOR 20 , OH, NHR 20 , SO 3 H, PO 3 H, aryl substituted with 0-3 R 20 , heterocycle substituted with 0-3 R 20 , C 1 -C 5  alkyl substituted with 0-1 R 21 , C 1 -C 5  alkoxy substituted with 0-1 R 21 , and a bond to C h ;  
 R 20  is independently selected at each occurrence from the group: H, aryl substituted with 0-1 R 21 , heterocycle substituted with 0-1 R 21 , cycloalkyl substituted with 0-1 R 21 , polyalkylene glycol substituted with 0-1 R 21 , carbohydrate substituted with 0-1 R 21 , cyclodextrin substituted with 0-1 R 21 , amino acid substituted with 0-1 R 21 , polycarboxyalkyl substituted with 0-1 R 21 , polyazaalkyl substituted with 0-1 R 21 , peptide substituted with 0-1 R 21 , wherein said peptide is comprised of 2-10 amino acids, and a bond to C h ;  
 R 21  is a bond to C h ;  
 k′ is 0-2;  
 h′ is 0-2;  
 h″ is 0-5;  
 h″′ is 0-2;  
 gu′ is 0-10;  
 g″′ is 0-10;  
 C h  is a metal bonding unit having a formula selected from the group:  
                     
 Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , Q 6 , Q 7 , and Q 8  are independently selected at each occurrence from the group: 
 NR 22 , NR 22 R 23 , S, SH, S(Pg), O, OH, PR 22 , PR 22 R 23 , P(NR 24 )R 25 R 26 , P(O)R 25 R 26 , and P(S) R 25 R 26 ;  
 
 E is a bond, CH, or a spacer group selected from the group: C 1 -C 10  alkyl substituted with 0-3 R 27 , aryl substituted with 0-3 R 27 , cycloalkyl substituted with 0-3 R 27 , heterocycloalkyl substituted with 0-3 R 27 , aralkyl substituted with 0-3 R 27 , and alkaryl substituted with 0-3 R 27 ;  
 E a  is a C 1 -C 10  alkyl group or a C 3 -C 14  carbocycle;  
 R 22 , R 23 , and R 24  are each independently selected from the group: a bond to L n′ , hydrogen, C 1 -C 10  alkyl substituted with 0-3 R 27 , aryl substituted with 0-3 R 27 , cycloalkyl substituted with 0-3 R 27 , heterocycloalkyl substituted with 0-3 R 27 , aralkyl substituted with 0-3 R 27 , alkaryl substituted with 0-3 R 27 , heterocycle substituted with 0-3 R 27 , and an electron, provided that when one of R 22  or R 23  is an electron, then the other is also an electron;  
 additionally, R 22  and R 23  may combine to form ═C(R 30 )(R 31 );  
 R 25  and R 26  are each independently selected from the group: a bond to L n′ , —OH, C 1 -C 10  alkyl substituted with 0-3 R 27 , C 1 -C 10  alkyl substituted with 0-3 R 27 , aryl substituted with 0-3 R 27 , cycloalkyl substituted with 0-3 R 27 , heterocycloalkyl substituted with 0-3 R 27 , aralkyl substituted with 0-3 R 27 , alkaryl substituted with 0-3 R 27 , and heterocycle substituted with 0-3 R 27 ;  
 R 27  is independently selected at each occurrence from the group: a bond to L n′ , ═O, F, Cl, Br, I, —CF 3 , —CN, —CO 2 R 28 , —C(═O)R 28 , —C(═O)N(R 28 ) 2 , —CHO, —CH 2 OR 28 , —OC(═O)R 28 , —OC(═O)OR 28a , —OR 28 , —OC(═O)N(R 28 ) 2 , —NR 29 C(═O)R 28 , —NR 29 C(═O)OR 28a , —NR 29 C(═O)N(R 28 ) 2 , —NR 29 SO 2 N(R 28 ) 2 , —NR 29 SO 2 R 28a , —SO 3 H, SO 2 R 28a , —SR 28 , —S(═O)R 28a , —SO 2 N(R 28 ) 2 , —N(R 28 ) 2 , —NHC(═NH)NHR 28 , —C(═NH)NHR 28 , ═NOR 28 , NO 2 , —C(═O)NHOR 28 , —C(═O)NHNR 28 R 28a , —OCH 2 CO 2 H, 2-(1-morpholino)ethoxy, C 1 -C 5  alkyl, C 2 -C 4  alkenyl, C 3 -C 6  cycloalkyl, C 3 -C 6  cycloalkylmethyl, C 2 -C 6  alkoxyalkyl, aryl substituted with 0-2 R 28 , and a 5-10-membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O;  
 R 28 , R 28a , and R 29  are independently selected at each occurrence from the group: a bond to L n′ , H, C 1 -C 6  alkyl, phenyl, benzyl, C 1 -C 6  alkoxy, halide, nitro, cyano, and trifluoromethyl;  
 Pg is a thiol protecting group;  
 R 30  and R 31  are independently selected from the group: 
 H, C 1 -C 10  alkyl, —CN, —CO 2 R 34 , —C(═O)R 34 , —C(═O)N(R 34 ) 2 , C 2 -C 10  1-alkene substituted with 0-3 R 33 , C 2 -C 10  1-alkyne substituted with 0-3 R 33 , aryl substituted with 0-3 R 33 , unsaturated heterocycle substituted with 0-3 R 33 , and unsaturated carbocycle substituted with 0-3 R 33 ;  
 
 or, alternatively, R 30  and R 31 , may be taken together with the divalent carbon radical to which they are attached to form:  
                     
 wherein:  
 R 32  and R 33  may be independently selected from the group: H, R 34 , C 1 -C 10  alkyl substituted with 0-3 R 34 , C 2 -C 10  alkenyl substituted with 0-3 R 34 , C 2 -C 10  alkynyl substituted with 0-3 R 34 , aryl substituted with 0-3 R 34 , heterocycle substituted with 0-3 R 34 , and carbocycle substituted with 0-3 R 34 ;  
 or, alternatively, R 32 , R 33  may be taken together to form a fused aromatic or heterocyclic ring;  
 c and d indicate the positions of optional double bonds and n is 0 or 1,  
 R 34  is independently selected at each occurrence from the group: ═O, F, Cl, Br, I, —CF 3 , —CN, —CO 2 R 35 , —C(═O)R 35 , —C(═O)N(R 35 ) 2 , —N(R 35 ) 3   + —CH 2 OR 35 , —OC(═O)R 35 , OC(═O)OR 35a , —OR 35 , —OC(═O)N(R 35 ) 2 , —NR 36 C(═O)R 35 , —NR 36 C(═O)OR 35a , —NR 36 C(═O)N(R 35 ) 2 , —NR 36 SO 2 N(R 35 ) 2 , —NR 36 SO 2 R 35a , —SO 3 H, —SO 2 R 35a , —SR 35 , —S(═O)R 35a , —SO 2 N(R 35 ) 2 , —N(R 35 ) 2 , —NHC(═NH)NHR 35 , —C(═NH)NHR 35 ,═NOR 35 , —C(═O)NHOR 35 , —OCH 2 CO 2 H, 2-(1-morpholino)ethoxy;  
 R 35 , R 35a , and R 36  are each independently selected at each occurrence from the group: hydrogen, C 1 -C 6  alkyl;  
 Z is selected from the group:  
                     
 wherein,  
 A 10  is NR 41  or —C(R 41 )═CH—;  
 R 37  is selected from the group: C(═O)—R 42 , CH═CR 43 C(═O)—R 42 , CH 2 C(═O)—R 42 , and CH 2 CH 2 C(═O)—R 42 ;  
 R 38  is selected from the group: SR 44 , SCH 2 R 44 , and S(═O)R 44 ;  
 R 39  is selected from the group: C 1 -C 10  alkyl substituted with 0-3 R 44 , and C 1 -C 10  alkoxy substituted with 0-3 R 44 ;  
 R 40  is C(═O)—R 42 ;  
 R 41  is CH 2 C(═O)N(CH 3 )CH 2 CH 2 C 6 H 5 ;  
 R 42  is a bond to L n′ ;  
 R 43  is selected from the group: H and C 1 -C 3  alkyl  
 R 44  is phenyl substituted with 0-4 R 45 ;  
 R 45  is independently selected at each occurrence from the group: OR 46 , C(═O)OR 46 , —Cl, —Br, —F, and N(R 46 ) 2 ;  
 R 46  is independently selected at each occurrence from the group: H, and C 1 -C 10  alkyl; and  
 e indicates the position of an optional double bond;  
 and pharmaceutically acceptable salts thereof.  
 
     
     
         3 . A reagent of  claim 2 , wherein: 
 W e  is selected from the group:                          wherein,    A 1  is N, C—OH, or CH;    A 2  and A 3  are CH;    A 4  is CR 3 ;    A 5  is O;    A 6  is O or CH 2 ;    R 4  is independently selected from the group: 
 —F, —Cl, ═O, —N(R 6 )(R 7 ), and —CF 3 ;  
   R 5  is independently selected from the group: 
 —F, —Cl, —CF 3 , C 1 -C 3  alkyl, C 1 -C 3  alkoxy, and methylenedioxy;  
   X is O, CH 2  or CH═CH;    R 8 , R 9 , R 10  and R 11  are independently selected at each occurrence from the group: a bond to L n′ , H, C 1 -C 5  alkyl, and C 1 -C 5  alkoxy;    or alternatively, R 8  and R 9  or R 10  and R 11  may be taken together to form a 3-6 membered cycloalkyl;    C h  is selected from the group:                          wherein:    Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , Q 6 , Q 7 , and Q8 are independently selected at each occurrence from the group: 
 NR 22 , NR 22 R 23 , S, SH, S(Pg), OH;  
   E is a bond, CH, or a spacer group selected from the group: C 1 -C 10  alkyl substituted with 0-3 R 27 , aryl substituted with 0-3 R 27 , cycloalkyl substituted with 0-3 R 27 , and heterocycle substituted with 0-3 R 27 ;    E a  is CH or a C 3 -C 6  carbocycle;    R 22  and R 23  are each independently selected from the group: a bond to L n′ , hydrogen, C 1 -C 10  alkyl substituted with 0-3 R 27 , aryl substituted with 0-3 R 27 , heterocycle substituted with 0-3 R 27 , and an electron, provided that when one of R 22  or R 23  is an electron;    additionally, R 22  and R 23  may combine to form ═C(R 30 )(R 31 );    R 27  is independently selected at each occurrence from the group: a bond to L n′ , ═O, F, Cl, Br, I, —CF 3 , —CN, —CO 2 R 28 , —C(═O)R 28 , —C(═O)N(R 28 ) 2 , —CH 2 OR 28 , —OC(═O)R 28 , —OC(═O)OR 28a , —OR 28 , —OC(═O)N(R 28 ) 2 , —NR 29 C(═O)R 28 , —NR 29 C(═O)OR 28a , —NR 29 C(═O)N(R 28 ) 2 , —NR 29 SO 2 N(R 28 ) 2 ,    NR 29 S 2 R 28a , —SO 3 H, —SO 2 R 28a , —SR 28 , —S(═O)R 28a , —SO 2 N(R 28 ) 2 , —N(R 28 ) 2 , —NHC(═NH)NHR 28 , —C(═NH)NHR 28 , ═NOR 28 , NO 2 , —C(═O)NHOR 28 , —C(═O)NHNR 28 R 28a , —OCH 2 CO 2 H, and 2-(1-morpholino)ethoxy;    R 28 , R 28a , and R 29  are independently selected at each occurrence from the group: a bond to L n′ , H, and C 1 -C 6  alkyl;    R 30  and R 31  are independently selected from the group: 
 —CO 2 R 34 , C 2 -C 5  1-alkene substituted with 0-3 R 33 , C 2 -C 5  1-alkyne substituted with 0-3 R 33 , aryl substituted with 0-3 R 33 , and unsaturated heterocycle substituted with 0-3 R 33 ;  
   R 32  and R 33  may be independently selected from the group: 
 H, R 34 ;  
 or, alternatively, R 32 , R 33  may be taken together to form a fused aromatic or heterocyclic ring;  
   R 34  is independently selected at each occurrence from the group: —CO 2 R 35 , —C(═O)N(R 35 ) 2 , —CH 2 OR 35 , —OC(═O)R 35 , —OR 35 , —SO 3 H, —N(R 35 ) 2 , and —OCH 2 CO 2 H;    R 35 , R 35a , and R 36  are each independently selected at each occurrence from the group: hydrogen, C 1 -C 3  alkyl;    R 39  is selected from the group: C 1 -C 10  alkyl substituted with 0-1 R 44 , and C 1 -C 10  alkoxy substituted with 0-1 R 44 ;    R 43  is H; and    R 46  is independently selected at each occurrence from the group: H, and C 1 -C 5  alkyl.    
     
     
         4 . A reagent of  claim 3 , wherein: 
 R 1  is selected from the group: 
 H, —C(═NH)NH 2 , C 1 -C 6  alkyl substituted with 0-2 R 4 , C 1 -C 6  alkoxy substituted with 0-2 R 4 , aryl substituted with 0-2 R 5 , and heterocycle substituted with 0-2 R 5 ;  
   R 3  is —H, —OH or C 1 -C 3  alkoxy;    or alternatively, R 1  and R 3  can be taken together with the atoms to which they are attached to form a fused phenyl ring substituted with 0-2 R 5 ;    R 4  is independently selected from the group: 
 ═O, and —N(R 6 )(R 7 );  
   R 5  is independently selected from the group: 
 —F, C 1 -C 3  alkyl, C 1 -C 3  alkoxy, and methylenedioxy;  
   X is O, CH 2  or CH═CH;    R 8 , R 9 , R 10  and R 11  are independently selected at each occurrence from the group: a bond to L n′ , H, and C 1 -C 3  alkyl;    or alternatively, R 8  and R 9  or R 10  and R 11  may be taken together to form a 3-6 membered cycloalkyl;    W 1  is O;    M 1  is selected from the group: 
 phenyl substituted with 0-1 R 12 , heterocycle substituted with 0-1 R 12 , benzophenone substituted with 0-1 R 12 , and diphenylether substituted with 0-1 R 12 ;  
   R 12  is independently selected from the group: a bond to L n′ , —COOR 13 , C 1 -C 5  alkyl substituted with 0-1 R 14 , and C 1 -C 5  alkoxy substituted with 0-1 R 14 ;    M 2  is selected from the group: aryl substituted with 0-1 R 19 , cycloalkyl substituted with 0-3 R 19 , and heterocycle substituted with 0-1 R 19 ;    C h  is selected from:                          wherein,    Q 1  and Q 4  are SH or S(Pg);    Q 2  and Q 3  are NR 22 ;    E is independently selected from the group: 
 CHR 27 , CH 2 CHR 27 , CH 2 CH 2 CHR 27 , and CHR 27 C(═O);  
   R 22  is selected from the group: H, C 1 -C 6  alkyl substituted with 0-1 R 27 ; and    R 27  are independently selected from H and a bond to L n′ ,    and,                          wherein,    Q 1  is NH 2  or N═C(R 30 )(R 31 );    E is a bond;    Q 2  is NHR 23 , wherein R 23  is heterocycle substituted with R 27 , wherein the heterocycle is selected from pyridine and thiazole, R 27  is selected from C(═O)NHR 28  and C(═O) R 28 , and R 28  is a bond to L n′ ;    R 30  is selected from the group: —CO 2 R 35 , C 2 -C 3  1-alkene substituted with 0-1 R 34 , aryl substituted with 0-1 R 34 , and unsaturated heterocycle substituted with 0-1 R 34 ;    R 31  is H;    R 34  is independently selected at each occurrence from the group: —CO 2 R 34 , —OR 34 , —SO 3 H, and —N(R 34 ) 2 ;    R 35  is independently selected at each occurrence from the group: hydrogen, and methyl;    A 10  is NR 41 ;    R 39  is C 1 -C 10  alkoxy substituted with 1 R 44 ; and    R 45  is independently selected at each occurrence from the group: OH, C(═O)OH, —Cl, —F, and NH 2 .    
     
     
         5 . The reagents of  claim 4  that are: 
 4-ethyl-2-(4-fluorophenyl)-[5-[5,5-dimethyl-6-[[6-[[[(2-sulfonylphenyl)methylene]hydrazino]-3-pyridinyl]carbonyl]amino]hexyl]oxy]phenol;  
 4-ethyl-2-(4-fluorophenyl)-[5-[4-[[6-[[[(2-sulfonylphenyl)methylene]hydrazino]-3-pyridinyl]carbonyl]amino]butyl]oxy]phenol;  
 2-[[[5-[[(6-[(4,6-diphenyl-2-pyridinyl)oxy]-1-hexanamino]carbonyl]-2-pyridinyl]hydrazono]methyl]-benzenesulfonic acid;  
 2-[[[5-[[2,2-dimethyl-6-[(6-fluorophenyl-4-phenyl-2-pyridinyl)oxy]-1-hexanamino]carbonyl]-2-pyridinyl]hydrazono]methyl]-benzenesulfonic acid;  
 2-[[[5-[[N-[6-[(6-(4-fluorophenyl)-4-phenyl-2-pyridinyl)oxy]-hexanoyl]-tyrosine-O-[3-propanamino]]carbonyl]-2-pyridinyl]hydrazono]-methyl]-benzenesulfonic acid;  
 2-[[[5-[[N-[6-[(4,6-diphenyl-2-pyridinyl)oxy]-hexanoyl]-tyrosine-O-[3-propanamino]]carbonyl]-2-pyridinyl]hydrazono]-methyl]-benzenesulfonic acid;  
 2-[[[5-[[N-[6-[(4-(3,4-methylenedioxyphenyl)-6-phenyl-2-pyridinyl)oxy]-hexanoyl]-tyrosine-O-[3-propanamino]]carbonyl]-2-pyridinyl]hydrazono]-methyl]-benzenesulfonic acid;  
 2-[[[5-[[alpha-N-[6-[(4,6-diphenyl-2-pyridinyl)oxy]-hexanoyl]-lysine-epsilon-N-amino]carbonyl]-2-pyridinyl]hydrazono]-methyl]-benzenesulfonic acid;  
 4-ethyl-2-(4-fluorophenyl)-5-[(5,5-dimethyl-6-aminohexyl)oxy]phenol N-[4-(carboxy)benzyl]-N,N′-bis[2-thioethyl]-glycinamide Conjugate;  
 Benzenesulfonic Acid, 2-[[[5-[[[6-[(4,6-diphenyl-2-pyridinyl)oxy]-2,2-dimethyl-1-hexyl]aza]carbonyl]-2-pyridinyl]hydrazono]methyl];  
 2-[[[5-[[[[6-[(4,6-Diphenyl-2-pyridinyl)oxy]-hexanoyl]-4-sulfonamidyl]benzylamino]carbonyl]-2-pyridinyl]hydrazono]methyl]-benzenesulfonic acid;  
 4-ethyl-2-(4-fluorophenyl)-[5-[6,6-dimethyl-7-[[6-[[[(2-sulfonylphenyl)methylene]hydrazino]-3-pyridinyl]carbonyl]amino]heptyl]oxy]phenol;  
 4-ethyl-2-(5-pyrazolyl)-[5-[5,5-dimethyl-6-[[6-[[[(2-sulfonylphenyl)methylene]hydrazino]-3-pyridinyl]carbonyl]amino]hexyl]oxy]phenol;  
 the Conjugate Between 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]pentyl]-6-(8-amino-5-aza-4-oxooctyloxy)benzenepropanoic Acid and Benzenesulfonic Acid, 2-[[[5-[[(2,5-Dioxo-1-pyrrolidinyl)oxy]carbonyl]-2-pyridinyl]hydrazono]methyl];  
 the Conjugate Between 6-(11-Amino-3,6,9-trioxaundecyloxy)-2-[5-[(5-oxo-1-(2-propenyl)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid and Benzenesulfonic Acid, 2-[[[5-[[(2,5-Dioxo-1-pyrrolidinyl)oxy]carbonyl]-2-pyridinyl]hydrazono]methyl];  
 4-ethyl-2-(4-fluorophenyl)-[5-[6,6-dimethyl-7-[[6-[[[phenylmethylene]hydrazino]-3-pyridinyl]carbonyl]amino]heptyl]oxy]phenol;  
 N-((6-((1-aza-2-phenylvinyl)amino)(3-pyridyl))sulfonyl)-3-(1-((N-(2-phenylethyl)carbamoyl)methyl)-5-(phenylmethoxy)indol-3-yl)prop-2-enamide;  
 propyl 3-((7-(3-(6-ethyl-4-(4-fluorophenyl)-3-hydroxyphenoxy)propoxy)-8-propylchroman-2-yl)carbonylamino)propanoate, 2-(2-aza-2-((5-carbamoyl(2-pyridyl)amino)vinyl)benzenesulfonic acid;  
 3-((7-(-(6-ethyl-4-(4-fluorophenyl)-3-hydroxyphenoxy)propoxy)-8-propylchroman-2-yl)carbonylamino)propyl-2-methylpropanoate, 2-(2-aza-2((5-carbamoyl(2-pyridyl)amino)vinyl)benzenesulfonic acid;  
 N-(3-((7-(3-(6-ethyl-4-(4-fluorophenyl)-3-hydroxyphenoxy)propoxy)-8-propylchroman-2-yl)carbonylamino)propyl)-2-methylpropanamide, 2-(2-aza-2-((5-carbamoyl(2-pyridyl))amino)vinyl)benzenesulfonic acid;  
 2-(2-aza-2-((5-(N-(6-(6-ethyl-3-hydroxy-4-(1-methylpyrazol-5-yl)phenoxy)-22-dimethylhexyl)carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic acid;  
 2-(2-aza-2-((5-(N-(6-(6-ethyl-3-hydroxy-4-(1-methylpyrazol-5-yl)phenoxy)-2,2-dimethylhexyl)carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic acid;  
 2-(2-aza-2-((5-((3-((6-ethyl-4-(4-fluorophenyl)-3-hydroxyphenoxy)methyl)piperidyl)carbonyl)(2-pyridyl))amino)vinyl)benzenesulfonic acid;  
 2-(((4-(N-(6-(4,6-Diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)phenyl)methyl)(2-sulfanylethyl)amino)-N-(2-sulfanylethyl)ethanamide;  
 2-(2-Aza-2-((5-(N-(3-(2-(2-(3-(5-(4-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,5-tetraazolyl))pentanoylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic Acid;  
 2-(2-Aza-2-((5-(N-(3-(2-(2-(3-(5-(5-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,4-tetraazolyl))pentanoylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic Acid;  
 2-(2-Aza-2-((5-(N-(2-(2-(2-(2-(2-(2-(2-(2-(5-(4-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,5-tetraazolyl))pentanoylamino)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic Acid;  
 2-(2-Aza-2-((5-(N-(5-(4-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,5-tetraazolyl))pentanoylamino)-1-(6-deoxy-β-cyclodextryl)carbamoyl)pentyl)carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic Acid;  
 2-(2-Aza-2-((5-(N-(3-(2-(2-(3-(2-(5-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,4-tetraazolyl))acetylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic Acid;  
 2-(2-Aza-2-((5-(N-(3-(2-(2-(3-(2-(4-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,5-tetraazolyl))acetylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic Acid;  
 3-(6-(3-(N-(5-((6-((1-Aza-2-(sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)-5-(N-(ω-methoxypolyethylene(750)glycoxyethyl)carbamoyl)pentyl)carbamoyl)propoxy)2-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic Acid;  
 3-(6-(3-(N-(3-(2-(2-(3-((6-((1-Aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)propoxy)2-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic Acid;  
 3-(6-(3-(N-(5-((6-((1-Aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)-5-(N-(2,3,4,5,6-pentahydroxyhexyl)carbamoyl)pentyl)carbamoyl)propoxy)2-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic Acid;  
 3-(6-(3-(N-(3-((6-((1-Aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)propyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid;  
 3-(6-(3-N-(2-(2-(2-(2-(2-(2-(2-(2-((6-((1-Aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid;  
 3-(6-(3-N-(5-((6-((1-Aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)-5-(N-(2,3,4,5,6-pentahydroxyhexyl)carbamoyl)pentyl)carbamoyl)propoxy-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid;  
 3-(6-(3-N-(5-((6-((1-Aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)-5-(N-(6-deoxy-β-cyclodextryl)carbamoyl)pentyl)carbamoyl)propoxy-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid;  
 3-(6-(3-(N-(3-((6-((1-Aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl))-Gly—Lys—Lys—Lys)aminopropyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid;  
 2-Sulfobenzaldehyde (E)-N-[3-(6-Hydrazinonicotinamido)propyl]-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenamide Hydrazone;  
 2-Sulfobenzaldehyde (E)-N-[3-(6-Hydrazinonicotinamido)propyl]-3-[6-[(phenylthio)methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenamide Hydrazone;  
 2-Sulfobenzaldehyde (E)-N-[3-(6-Hydrazinonicotinamido)propyl]-3-[6-[[(2-chlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenamide Hydrazone;  
 2-Sulfobenzaldehyde (E)-N-[3-(6-Hydrazinonicotinamido)propyl]-3-[6-[[(2,6-dimethylphenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenamide Hydrazone;  
 2-Sulfobenzaldehyde (E)-N-[3-(6-Hydrazinonicotinamido)propyl]-3-[6-[[(2,3,5,6-tetrafluorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenamide Hydrazone;  
 2-Sulfobenzaldehyde (E)-N-[3-(6-Hydrazinonicotinamido)propyl]-3-[6-[[(4-hydroxyphenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenamide Hydrazone;  
 2-Sulfobenzaldehyde (E)-N-[2-(6-Hydrazinonicotinamido)ethyl]-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propanamide Hydrazone;  
 2-Sulfobenzaldehyde N-[3-(6-Hydrazinonicotinamido)propyl]-1-[3-([1,1′-biphenyl]-4-ylmethyl)-2H-1-benzopyran-7-yl]cyclopentanecarboxamide Hydrazone;  
 2-Sulfobenzaldehyde 6-[5-(6-Hydrazinonicotinamido)pentyloxy]-5-(2-propenyl)-1,2,3,4-tetrahydronaphthalen-1-one Hydrazone;  
 2-Sulfobenzaldehyde 6-[6-(6-Hydrazinonicotinamido)hexyloxy]-5-(2-propenyl)-1,2,3,4-tetrahydronaphthalen-1-one Hydrazone;  
 2-Sulfobenzaldehyde 6-[6-(6-Hydrazinonicotinamido)-4,4-dimethylpentyloxy]-5-(2-propenyl)-1,2,3,4-tetrahydronaphthalen-1-one Hydrazone;  
 2-Sulfobenzaldehyde 6-[6-(6-Hydrazinonicotinamido)-5,5-dimethylhexyloxy]-5-(2-propenyl)-1,2,3,4-tetrahydronaphthalen-1-one Hydrazone;  
 2-Sulfobenzaldehyde 6-[4-(6-Hydrazinonicotinamido)butoxy]-5-(2-propenyl)-1,2,3,4-tetrahydronaphthalen-1-one Hydrazone;  
 2-Sulfobenzaldehyde 6-[3-(6-Hydrazinonicotinamido)propoxy]-5-(2-propenyl)-1,2,3,4-tetrahydronaphthalen-1-one Hydrazone;  
 2-Sulfobenzaldehyde 6-[2-(6-Hydrazinonicotinamido)ethoxy]-5-(2-propenyl)-1,2,3,4-tetrahydronaphthalen-1-one Hydrazone;  
 2-[[[5-[[2,2-Dimethyl-6-[(4-(3,4-methylenedioxyphenyl)-6-phenyl-2-pyridinyl)oxy]-1-hexanamino]carbonyl]-2-pyridinyl]hydrazono]methyl]-benzenesulfonic acid;  
 N-[2,2-Dimethyl-6-[(4-(3,4-methylenedioxyphenyl)-6-phenyl-2-pyridinyl)oxy]-hexyl]-bis-S-(1-ethoxyethylmercapto-acetyl)pentanoate;  
 2-[[[5-[[N-[6-[(4,6-diphenyl-2-pyridinyl)oxy]-hexanoyl]-glycine-alpha-amino]carbonyl]-2-pyridinyl]hydrazono]-methyl]-benzenesulfonic acid;  
 2-Acetyl-4-ethyl-[5-[6-[[6-[[[(2-sulfonylphenyl)methylene]hydrazino]-3-pyridinyl]carbonyl]amino]hexyl]oxy]phenol;  
 2,4-Diethyl-[5-[5,5-dimethyl-6-[[6-[[[(2-sulfonylphenyl)methylene]hydrazino]-3-pyridinyl]carbonyl]amino]hexyl]oxy]phenol;  
 3-(4-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)-3-ethoxyphenyl)-N-((6-hydrazino(3-pyridyl))sulfonyl)prop-2-enamide;  
 2-((6-((1-aza-2-(2-sulfophenyl)vinyl)-amino)(3-pyridyl))carbonyl)-7-(5-(4,6-diphenyl(2-pyridyl-oxy))pentyloxy)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid;  
 2-((6-((1-aza-2-(2-sulfophenyl)vinyl)-amino)(3-pyridyl)carbonylamino)-3-(4-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic acid;  
 2-((6-((1-aza-2-(2-sulfophenyl)vinyl)-amino)(3-pyridyl)carbonylamino)-3-(2-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic acid;  
 3-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl)carbonylamino)-3-(N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)propanoic acid;  
 2-(2-aza-2-((5-(N-(3-(2-(2-(3-((1-((N-methyl-N-(2-phenylethyl)carbamoyl)methyl)-5-(phenylmethoxy)-indol-2-yl)carbonylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic acid;  
 2-(2-((6-((1-aza-2-(2-sulfophenyl)vinyl)-amino)(3-pyridyl)carbonylamino)-3-carboxypropanoylamino)-3-(2-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic acid;  
 2-(2-aza-2-((5-(N-(2-(N-(3-(2-(2-(3-(2-(2,5-dioxoimidazolidin-4-yl)acetylamino)-propoxy)ethoxy)ethoxy)propyl)carbamoyl)-1-(N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)-ethyl)carbamoyl(2-pyridyl))amino)-vinyl)benzenesulfonic acid;  
 6-((6-((1-aza-2-(2-sulfophenyl)-vinyl)amino)(3-pyridyl)carbonylamino)-2-((1-((N-methyl-N-(2-phenylethyl)carbamoyl)methyl)-5-(phenylmethoxy)indol-2-yl)carbonylamino)hexanoic acid;  
 1-(3-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)-(3-pyridyl)carbonylamino)-3-(N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)propanoylamino)ethane-1,2-dicarboxylic acid;  
 1-(2-(3-((6-((1-aza-2-(2-sulfophenyl)vinyl)-amino))(3-pyridyl)carbonylamino)-3-(N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)propanoylamino)-3-carboxypropanoylamino)ethane-1,2-dicarboxylic acid;  
 2-(2-aza-2-((5-(N-(1-(N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)-2-(3-(((4,5,6-trihydroxy-3-(hydroxymethyl)(2-oxanyl))amino)carbonylamino)propanoylamino)ethyl)carbamoyl(2-pyirdyl))amino)vinyl)benzenesulfonic acid;  
 2-(2-aza-2-((5-((6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexanoyl-amino)sulfonyl)-(2-pyridyl))amino)vinyl)benzenesulfonic acid;  
 6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-N-(1-(N-((6-hydrazino(3-pyridyl))sulfonyl)cabamoyl)-2-(4-hydroxyphenyl)ethyl)-2,2-dimethylhexanamide;  
 4-(4,6-diphenyl(2-pyridyloxy))-N-(1-(N-(1-(N-((6-hydrazino(3-pyridyl))sulfonyl)cabamoyl)-2-(4-hydroxyphenyl)ethyl)carbamoyl)-isopropyl)butanamide;  
 3-(4-(3-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)-propoxy)phenyl)-2-(2,2-dimethyl-6-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))hexanoylamino)propanoic acid;  
 3-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl)carbonylamino)-3-(N-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)propanoic acid;  
 2-(2-aza-2-((5-(N-(1-(N-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethyl-hexyl)carbamoyl)-2-(4-hydroxyhenyl)ethyl)carbamoyl(2-pyridyl))amino)vinyl)benzenesulfonic acid;  
 2-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl)carbonylamino)-2-(2,2-dimethyl-6-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))hexanoylamino)acetic acid;  
 2-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl)carbonylamino)-2-(2,2-dimethyl-6-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))hexanoylamino)acetic acid;  
 3-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl)carbonylamino)-3-(N-(6-(6-ethyl-3-hydroxy-4-phenylphenoxy)-2,2-dimethylhexyl)carbamoyl)propanoic acid;  
 2-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl)carbonylamino)-2-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexanoylamino)acetic acid;  
 2-(2-aza-2-((5-(N-(5-((3-((N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexanoylamino)-3-(4-hydroxyphenyl)propanoylamino)-1-(N-(2,3,4,5,6-pentahydroxyhexyl)carbamoyl)pentyl)carbamoyl(2-pyridyl))amino)vinyl)benzenesulfonic acid;  
 2-(2-aza-2-((5-(N-(5-((3-((N-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)-2-(N-(2,3,4,5,6-pentahydroxyhexyl)carbamoyl)ethyl)carbamoyl(2-pyridyl))amino)vinyl)benzenesulfonic acid;  
 2-(2-aza-2-((5-(N-(5-((3-((N-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)amino)phenyl)carbonylamino)-1-(N-(2,3,4,5,6-pentahydroxyhexyl)carbamoyl)pentyl)carbamoyl(2-pyridyl))amino)vinyl)benzenesulfonic acid;  
 2-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)-3-(N-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)-propanoylamino)-3-carboxypropanoylamino)-3-carboxypropanoylamino)-ethane-1,2-dicarboxylic acid;  
 2-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)-3-(2-(5-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic acid.  
 
     
     
         6 . A kit comprising a reagent of  claim 1 .  
     
     
         7 . The kit of  claim 6  further comprising a reducing agent.  
     
     
         8 . The kit of  claim 7  wherein the reducing agent is tin(II).  
     
     
         9 . The kit of  claim 6  further comprising one or more ancillary ligands.  
     
     
         10 . The kit of  claim 7  further comprising one or more ancillary ligands.  
     
     
         11 . The kit of  claim 8  further comprising one or more ancillary ligands.  
     
     
         12 . The kit of  claim 9  wherein the ancillary ligands are tricine and TPPTS.  
     
     
         13 . The kit of  claim 10  wherein the ancillary ligands are tricine and TPPTS.  
     
     
         14 . The kit of  claim 11  wherein the anicillary ligands are tricine and TPPTS.  
     
     
         15 . A radiolabeled LTB4 binding agent wherein the radioisotope is selected from  99m Tc,  111 In,  95 Tc,  62 Cu,  67 Ga,  68 Ga,  123 I,  125 I,  18 F,  11 C,  13 N,  15 O, and  75 Br.  
     
     
         16 . The radiolabeled LTB4 binding agent of  claim 15  wherein the radioisotope is  123 I.  
     
     
         17 . The radiolabeled LTB4 binding agent of  claim 15  wherein the radioisotope is  111 In.  
     
     
         18 . The radiolabeled LTB4 binding agent of  claim 15  wherein the radioisotope  99m Tc.  
     
     
         19 . A radiolabeled LTB4 binding agent prepared from a reagent of  claim 1  wherein the radioisotope is  99m Tc.  
     
     
         20 . A radiolabeled LTB4 binding agent prepared from a kit of  claim 6  wherein the radioisotope is  99 mTC.  
     
     
         21 . The radiolabeled LTB4 binding agents of  claim 18  that are: 
   99m Tc(tricine)(TPPTS)(4-ethyl-2-(4-fluorophenyl)-[5-[5,5-dimethyl-6-[[[6-diazenido-3-pyridinyl]carbonyl]amino]hexyl]oxy]phenol);  
   99m Tc(tricine)(TPPDS)(4-ethyl-2-(4-fluorophenyl)-[5-[5,5-dimethyl-6-[[[6-diazenido-3-pyridinyl]carbonyl]amino]hexyl]oxy]phenol);  
   99m Tc(tricine)(TPPMS)(4-ethyl-2-(4-fluorophenyl)-[5-[5,5-dimethyl-6-[[[6-diazenido-3-pyridinyl]carbonyl]amino]hexyl]oxy]phenol);  
   99m Tc(tricine)(3-sulfonatopyridine))(4-ethyl-2-(4-fluorophenyl)-[5-[5,5-dimethyl-6-[[[6-diazenido-3-pyridinyl]carbonyl]amino]hexyl]oxy]phenol);  
   99m Tc(tricine)(TPPTS)(4-ethyl-2-(4-fluorophenyl)-[5-[4-[[[6-diazenido-3-pyridinyl]carbonyl]amino]butyl]oxy]phenol);  
   99m Tc(tricine)(TPPTS)(2-[[5-[[(6-[(4,6-diphenyl-2-pyridinyl)oxy]-1-hexanamino]carbonyl]-2-pyridinyl]diazenido]);  
   99m Tc(tricine)(TPPTS)(2-[[5-[[2,2-dimethyl-6-[(6-fluorophenyl-4-phenyl-2-pyridinyl)oxy]-1-hexanamino]carbonyl]-2-pyridinyl]diazenido]);  
   99m Tc(tricine)(TPPTS)(2-[[5-[[N-[6-[(4,6-diphenyl-2-pyridinyl)oxy]-hexanoyl]-tyrosine-O-[3-propanamino]]carbonyl]-2-pyridinyl]diazenido]);  
   99m Tc(tricine)(TPPTS)(2-[[[5-[[N-[6-[(4-(3,4-methylenedioxyphenyl)-6-phenyl-2-pyridinyl)oxy]-hexanoyl]-tyrosine-O-[3-propanamino]]-carbonyl]-2-pyridinyl]diazenido]);  
   99m Tc(tricine)(TPPTS)(2-[[[5-[[alpha-N-[6-[(4,6-diphenyl-2-pyridinyl)oxy]-hexanoyl]-lysine-epsilon-N-amino]carbonyl]-2-pyridinyl]diazenido]);  
   99m Tc(tricine)(TPPTS)(2-[[[5-[[[6-[(4,6-diphenyl-2-pyridinyl)oxy]-2,2-dimethyl-1-hexyl]aza]carbonyl]-2-pyridinyl]diazenido]);  
   99m Tc(tricine)(TPPTS)(4-ethyl-2-(4-fluorophenyl)-[5-[6,6-dimethyl-7-[[6-[[6-diazenido]-3-pyridinyl]carbonyl]amino]heptyl]oxy]phenol);  
   99m Tc(tricine)(TPPTS)(2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]pentyl]-6-(8-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-5-aza 4 oxooctyloxy)benzenepropanoic Acid);  
   99m Tc(tricine)(3-pyridinesulfonic acid))(2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]pentyl]-6-(8-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-5-aza-4-oxooctyloxy)benzenepropanoic Acid);  
   99m Tc(tricine)(3,5-pyridinedicarboxylic acid)(2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy[pentyl]-6-(8-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-5-aza-4-oxooctyloxy)benzenepropanoic Acid);  
   99m Tc(tricine)(TPPTS)(6-(11-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-3,6,9-trioxaundecyloxy)-2-[5-[(5-oxo-1-(2-propenyl)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid);  
   99m Tc(tricine)(TFP)(6-(11-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-3,6,9-trioxaundecyloxy)-2-[5-[(5-oxo-1-(2-propenyl)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid);  
   99m Tc(tricine)(3,5-pyridinedicarboxylic acid)(6-(11-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-3,6,9-trioxaundecyloxy)-2-[5-[(5-oxo-1-(2-propenyl)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid);  
   99m Tc(tricine)(isonicotinic acid)(6-(11-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-3,6,9-trioxaundecyloxy)-2-[5-[(5-oxo-1-(2-propenyl)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid);  
   99m Tc(tricine)(nicotinic acid)(6-(11-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-3,6,9-trioxaundecyloxy)-2-[5-[(5-oxo-1-(2-propenyl)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid);  
   99m Tc(tricine)(3-pyridinesulfonic acid)(6-(11-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-3,6,9-trioxaundecyloxy)-2-[5-[(5-oxo-1-(2-propenyl)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid);  
   99m Tc(tricine)(hydroxyethylisonicotinamide)(6-(11-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-3,6,9-trioxaundecyloxy)-2-[5-[(5-oxo-1-(2-propenyl)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid);  
   99m Tc(tricine)(4-methyl-5-imidazolemethanol)(6-(11-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-3,6,9-trioxaundecyloxy)-2-[5-[(5-oxo-1-(2-propenyl)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid);  
   99m Tc(tricine)(4-methyl-5-thiazoleethanol)(6-(11-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-3,6,9-trioxaundecyloxy)-2-[5-[(5-oxo-1-(2-propenyl)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid);  
   99m Tc(tricine)(pyridine)(6-(11-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-3,6,9-trioxaundecyloxy)-2-[5-[(5-oxo-1-(2-propenyl)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid);  
   99m Tc(tricine)(4-pyridylethylsulfonic acid)(6-(11-[[[6-diazenido]-3-pyridinyl]carbonyl]amino-3,6,9-trioxaundecyloxy)-2-[5-[(5-oxo-1-(2-propenyl)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]pentyloxy]benzenepropanoic Acid);  
   99m Tc(tricine)(TPPTS)(N-((6-(diazenido)(3-pyridyl))sulfonyl)-3-(1-((N-(2-phenylethyl)carbamoyl)methyl)-5-(phenylmethoxy)indol-3-yl)prop-2-enamide);  
   99m Tc(tricine)(TPPTS)((2-((5-carbamoyl(2-pyridyl)diazenido) ethyl 3-((7-(3-(6-ethyl-4-(4-fluorophenyl)-3-hydroxyphenoxy)propoxy)-8-propylchroman-2-yl)carbonylamino)propanoate);  
   99m Tc(tricine)(TPPTS)(3-((7-(-(6-ethyl-4-(4-fluorophenyl)-3-hydroxyphenoxy)propoxy)-8-propylchroman-2-yl)carbonylamino)propyl-2-methylpropanoate, 2-(2((5-carbamoyl(2-pyridyl)diazenido);  
   99m Tc(tricine)(TPPTS)(N-(3-((7-(3-(6-ethyl-4-(4-fluorophenyl)-3-hydroxyphenoxy)propoxy)-8-propylchroman-2-yl)carbonylamino)propyl)-2-methylpropanamide, 2-(2-((5-carbamoyl(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(2-(2-((5-(N-(6-(6-ethyl-3-hydroxy-4-(1-methylpyrazol-5-yl)phenoxy)-2,2-dimethylhexyl)carbamoyl)(2-pyridyl))diazenido);  
   99m Tc(tricine)(3-pyridinesulfonic acid)(2-(2-((5-(N-(6-(6-ethyl-3-hydroxy-4-(1-methylpyrazol-5-yl)phenoxy)-2,2-dimethylhexyl)carbamoyl)(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(2-(2-((5-((3-((6-ethyl-4-(4-fluorophenyl)-3-hydroxyphenoxy)methyl)piperidyl)carbonyl)(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(2-(2-((5-(N-(3-(2-(2-(3-(5-(5-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,4-tetraazolyl))pentanoylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(2-(2-((5-(N-(2-(2-(2-(2-(2-(2-(2-(2-(5-(4-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,5-tetraazolyl))pentanoylamino)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(2-(2-((5-(N-(5-(4-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,5-tetraazolyl))pentanoylamino)-1-(6-deoxy-β-  
   99m Tc(tricine)(pyridine)(3-(6-(3-(N-(3-((6-(diazenido)(3-pyridyl))carbonylamino)propyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid);  
   99m Tc(tricine)(TPPTS)(3-(6-(3-N-(2-(2-(2-(2-(2-(2-(2-(2-((6-(diazenido)(3-pyridyl))carbonylamino)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid);  
   99m Tc(tricine)(TPPTS)(3-(6-(3-N-(5-((6-(diazenido)(3-pyridyl))carbonylamino)-5-(N-(2,3,4,5,6-pentahydroxyhexyl)carbamoyl)pentyl)carbamoyl)propoxy-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid);  
   99m Tc(tricine)(TPPTS)(3-(6-(3-N-(5-((6-(diazenido)(3-pyridyl))carbonylamino)-5-(N-(6-deoxy-β-cyclodextryl)carbamoyl)pentyl)carbamoyl)propoxy-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid);  
   99m Tc(tricine)(TPPTS)(3-(6-(3-(N-(3-((6-((diazenido)(3-pyridyl))-Gly—Lys—Lys—Lys)aminopropyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid);  
   99m Tc(tricine)(TPPTS)((E)-N-[3-(6-diazenidonicotinamido)propyl]-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenamide);  
   99m Tc(tricine)(TPPTS)((E)-N-[3-(6-diazenidonicotinamido)propyl]-3-[6-[(phenylthio)methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenamide); cyclodextryl)carbamoyl)pentyl)carbamoyl)(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(3-(6-(3-(N-(5-((6-(diazenido)(3-pyridyl))carbonylamino)-5-(N-(ω-methoxypolyethylene(750)glycoxyethyl)carbamoyl)pentyl)carbamoyl)propoxy)2-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic Acid);  
   99m Tc(tricine)(TPPTS)(3-(6-(3-(N-(3-(2-(2-(3-((6-(diazenido)(3-pyridyl))carbonylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)propoxy)2-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic Acid);  
   99m Tc(tricine)(TPPTS)(3-(6-(3-(N-(5-((6-(diazenido)(3-pyridyl))carbonylamino)-5-(N-(2,3,4,5,6-pentahydroxyhexyl)carbamoyl)pentyl)carbamoyl)propoxy)2-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic Acid);  
   99m Tc(tricine)(TFP)(3-(6-(3-(N-(5-((6-(diazenido)(3-pyridyl))carbonylamino)-5-(N-(2,3,4,5,6-pentahydroxyhexyl)carbamoyl)pentyl)carbamoyl)propoxy)2-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic Acid);  
   99m Tc(tricine)(TPPTS)(3-(6-(3-(N-(3-((6-(diazenido)(3-pyridyl))carbonylamino)propyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid);  
   99m Tc(tricine)(TFP)(3-(6-(3-(N-(3-((6-(diazenido)(3-pyridyl))carbonylamino)propyl)carbamoyl)propoxy)-2-(5-(5-oxo-1-prop-2-enyl(2-6,7,8-trihydronaphthyloxy))pentyloxy)phenyl)propanoic Acid);  
   99m Tc(tricine)(TPPTS)((E)-N-[3-(6-diazenidonicotinamido)propyl]-3-[6-[[(2-chlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenamide);  
   99m Tc(tricine)(TPPTS)((E)-N-[3-(6-diazenidonicotinamido)propyl]-3-[6-[[(2,6-dimethylphenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenamide);  
   99m Tc(tricine)(TPPTS)((E)-N-[3-(6-diazenidonicotinamido)propyl]-3-[6-[[(2,3,5,6-tetrafluorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenamide);  
   99m Tc(tricine)(TPPTS)((E)-N-[3-(6-diazenidonicotinamido)propyl]-3-[6-[[(2,3,5,6-tetrafluorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenamide);  
   99m Tc(tricine)(TPPTS)((E)-N-[2-(6-diazenidonicotinamido)ethyl]-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propanamide);  
   99m Tc(tricine)(TPPTS)(6-[6-(6-diazenidonicotinamido)-4,4-dimethylpentyloxy]-5-(2-propenyl)-1,2,3,4-tetrahydronaphthalen-1-one);  
   99m Tcc(tricine)(TPPTS)(2-[[[5-[[2,2-Dimethyl-6-[(4-(3,4-methylenedioxyphenyl)-6-phenyl-2-pyridinyl)oxy]-1-hexanamino]carbonyl]-2-pyridinyl]diazenido);  
   99m Tc(tricine)(TPPTS)(2-[[[5-[[N-[6-[(4,6-diphenyl-2-pyridinyl)oxy]-hexanoyl]-glycine-alpha-amino]carbonyl]-2-pyridinyl]diazenido);  
   99m Tc(tricine)(TPPTS)(2,4-Diethyl-[5-[5,5-dimethyl-6-[[6-[[diazenido]-3-pyridinyl]carbonyl]amino]hexyl]oxy]phenol);  
   99m Tc(tricine)(TPPTS)(2-((6-(diazenido)(3-pyridyl)carbonylamino)-3-(2-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic acid);  
   99m Tc(tricine)(TPPTS)(3-((6-(diazenido)(3-pyridyl)carbonylamino)-3-(N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)propanoic acid);  
   99m Tc(tricine)(TPPTS)(2-(2-((6-(diazenido)(3-pyridyl)carbonylamino)-3-carboxypropanoylamino)-3-(2-(5-(4,6-diphenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic acid);  
   99m Tc(tricine)(TPPTS)(2-(2-((5-(N-(2-(N-(3-(2-(2-(3-(2-(2,5-dioxoimidazolidin-4-yl)acetylamino)propoxy)ethoxy)ethoxy)-propyl)carbamoyl)-1-(N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)ethyl)carbamoyl(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(1-(3-((6-(diazenido)-(3-pyridyl)carbonylamino)-3-(N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)propanoylamino)ethane-1,2-dicarboxylic acid);  
   99m Tc(tricine)(TPPTS)(2-(2-((5-(N-(1-(N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)-2-(3-(((4,5,6-trihydroxy-3-(hydroxymethyl)(2-oxanyl))amino)carbonylamino)propanoylamino)ethyl)carbamoyl(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(2-(2-((5-((6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexanoyl-amino)sulfonyl)-(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(3-((6-((diazenido)(3-pyridyl)carbonylamino)-3-(N-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)propanoic acid);  
   99m Tcc(tricine)(TFP)(3-((6-((diazenido)(3-pyridyl)carbonylamino)-3-(N-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)propanoic acid);  
   99m Tc(tricine)(TPPTS)(2-(2-((5-(N-(1-(N-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethyl-hexyl)carbamoyl)-2-(4-hydroxyphenyl)ethyl)carbamoyl(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(2-((6-(diazenido)(3-pyridyl)carbonylamino)-2-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexanoylamino)acetic acid);  
   99m Tc(tricine)(TPPTS)(2-(2-((5-(N-(5-((3-((N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexanoylamino)-3-(4-hydroxyphenyl)propanoylamino)-1-(N-(2,3,4,5,6-pentahydroxyhexyl)carbamoyl)pentyl)carbamoyl(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(2-(2-((5-(N-(5-((3-((N-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexyl)-carbamoyl)-2-(N-(2,3,4,5,6-pentahydroxyhexyl)carbamoyl)-ethyl)carbamoyl(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(2-(2-((5-(N-(5-((3-((N-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)amino)phenyl)carbonylamino)-1-(N-(2,3,4,5,6-pentahydroxyhexyl)carbamoyl)pentyl)carbamoyl(2-pyridyl))diazenido);  
   99m Tc(tricine)(TPPTS)(2-((6-(diazenido)(3-pyridyl))carbonylamino)-3-(N-(6-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)-propanoylamino)-3-carboxypropanoylamino)-3-carboxypropanoylamino)-ethane-1,2-dicarboxylic acid);  
   99m Tc(tricine)(TPPTS)(2-((6-(diazenido)(3-pyridyl))carbonylamino)-3-(2-(5-(4-benzo[d]1,3-dioxolan-5-yl-6-phenyl(2-pyridyloxy))pentyloxy)phenyl)propanoic acid);  
   99m TcO(4-ethyl-2-(4-fluorophenyl)-5-[(5,5-dimethyl-6-aminohexyl)oxy]phenol N-[4-(carboxy)benzyl]-N,N′-bis[2-thiolatoethyl]-glycinamide); and,  
   99m TcO(N-[2,2-Dimethyl-6-[(4-(3,4-methylenedioxyphenyl)-6-phenyl-2-pyridinyl)oxy]-hexyl]-bis(mercapto-acetyl)pentanoate).  
 
     
     
         22 . A method of detecting sites of infection and inflammation in a mammal comprising administering to said mammal a radiolabeled LTB4 binding agent and then detecting said sites using a radiation detecting probe.  
     
     
         23 . A method of imaging sites of infection and inflammation in a mammal comprising administering to said mammal a radiolabeled LTB4 binding agent and then imaging said sites using a planar or ring gamma camera.  
     
     
         24 . The method of  claim 23  wherein the radiolabeled binding agent is a radiolabeled binding agent of  claim 15 .  
     
     
         25 . A method of diagnosing disease in a mammal associated with infection and inflammation comprising imaging said mammal using a radiolabeled LTB4 binding agent and determining the presence of said disease.  
     
     
         26 . The method of  claim 25  wherein the radiolabeled binding agent is a radiolabeled binding agent of  claim 15 .  
     
     
         27 . A compound having the formula: 
       W e′ —O—(CR 54 R 55 ) k″ —Y′; 
       wherein, 
 W e′  is selected from the group:  
                     
 wherein,  
 R 47  is selected from the group: C 1 -C 6  alkyl substituted with 0-3 R 50 , C 1 -C 6  alkoxy substituted with 0-3 R 50 , aryl substituted with 0-3 R 51 , and heterocycle substituted with 0-3 R 51 ;  
 R 48  and R 49  are selected from the group: C 1 -C 3  alkyl, C 2 -C 3  alkenyl, cyclopropyl, cyclopropylmethyl, and aryl substituted with 0-3 R 51 ;  
 R 50  is independently selected from the group: —F, —Cl, —Br, —I, ═O, —N(R 52 )(R 53 ), and —CF 3 ;  
 R 51  is independently selected from the group: —F, —Cl, —Br, —I, —N(R 52 )(R 53 ), —CF 3 , C 1 -C 3  alkyl, C 1 -C 3  alkoxy, and methylenedioxy;  
 R 52  and R 53  are independently H or C 1 -C 3  alkyl;  
 R 54  and R 55  are independently selected at each occurrence from the group: H, C 1 -C 5  alkyl, and C 1 -C 5  alkoxy, or alternatively, R 54  and R 55  may be taken together to form a 3-6 membered cycloalkyl;  
 k″ is 4-7;  
 Y′ is selected from the group: C(═O)NHR 56 , NHC(═O)R 56 , and NHC(═O) NHR 57 ;  
 R 56  is selected from the group: aromatic heterocycle substituted with 0-3 R 58 , aryl substituted with 0-3 R 58 , and C 1 -C 5  alkyl substituted with 1-3 R 59 ;  
 R 57  is selected from the group: heterocycle substituted with 0-3 R 58 , aryl substituted with 0-3 R 58 , and C 1 -C 5  alkyl substituted with 0-3 R 60 ;  
 R 58  is independently selected at each occurrence from the group: —Cl, —F, —Br, —I, COOR 61 , OR 61 , C(═O)N(R 61 ) 2 , and C 1 -C 3  alkyl substituted with 0-3 R 62 ;  
 R 59  is independently selected at each occurrence from the group: —Cl, —F, —Br, —I, COOR 61 , OR 61 , C(═O)N(R 61 ) 2 , N(R 61 ) 2 , and NHC(═O)R 63 , provided that at least one R 59  is NH(C═O)R 63 ;  
 R 60  is independently selected at each occurrence from the group: —Cl, —F, —Br, —I, COOR 61 , OR 61 , C(═O)N(R 61 ) 2 , N(R 61 ) 2 , and NHC(═O)R 63 ;  
 R 61  is independently selected at each occurrence from the group: H, and C 1 -C 5  alkyl;  
 R 62  is independently selected at each occurrence from the group: —Cl, —F, —Br, —I, COOR 64 , OR 64 , C(═O)N(R 64 ) 2 , and NH(C═O) R 64 ;  
 R 63  is independently selected at each occurrence from the group: aryl substituted with 0-3 R 65 , and heterocycle substituted with 0-3 R 65 ;  
 R 64  is independently selected at each occurrence from the group: H, and C 1 -C 5  alkyl;  
 R 65  is independently selected at each occurrence from the group: —Cl, —F, —Br, —I, COOR 66 , OR 66 , and C(═O)N(R 66 ) 2 ; and  
 R 66  is independently selected at each occurrence from the group: H, and C 1 -C 5  alkyl;  
 and pharmaceutically acceptable salts thereof.  
 
     
     
         28 . A compound of  claim 27 , wherein: 
 R 50  is independently selected from the group: —F, —Cl, ═O, —N(R 52 )(R 53 ), and —CF 3 ;    R 51  is independently selected from the group: —F, —Cl, —CF 3 , C 1 -C 3  alkyl, C 1 -C 3  alkoxy, and methylenedioxy;    R 54  and R 55  are independently selected at each occurrence from the group: H, C 1 -C 3  alkyl, and C 1 -C 3  alkoxy;    k″ is 5-6;    R 56  is selected from the group: pyridine substituted with 0-3 R 58 , aryl substituted with 0-3 R 58 , and C 1 -C 3  alkyl substituted with 1-3 R 59 ;    R 57  is selected from the group: pyridine substituted with 0-3 R 58 , aryl substituted with 0-3 R 58 , and C 1 -C 3  alkyl substituted with 0-3 R 60 ;    R 58  is independently selected at each occurrence from the group: —Cl, —F, COOR 61 , OR 61 , and C(═O) N(R 61 ) 2 ;    R 59  is independently selected at each occurrence from the group: COOR 61 , OR 61 , C(═O)N(R 61 ) 2 , and NHC(═O)R 63 , provided that at least one R 59  is NH (C═O) R 63 ;    R 60  is independently selected at each occurrence from the group: COOR 61 , OR 61 , C(═O)N(R 61 ) 2 , and NHC(═O) R 63 ;    R 61  is independently selected at each occurrence from the group: H, and C 1 -C 5  alkyl;    R 63  is independently selected at each occurrence from the group: phenyl substituted with 0-3 R 65 , and pyridine substituted with 0-3 R 65 ; and,    R 65  is independently selected at each occurrence from the group: —Cl, —F, COOR 66 , and OR 66 .    
     
     
         29 . A compound of  claim 28 , wherein: 
 R 47  is phenyl or p-fluorophenyl;    R 48  is phenyl substituted with 0-1 R 51 ;    R 49  is C 2 -C 3  alkyl;    R 51  is —F or methylenedioxy;    R 54  and R 55  are independently H or methyl;    R 56  is selected from the group: 
 pyridine substituted with 0-1 R 58 , phenyl substituted with 0-1 R 58 , and C 1 -C 3  alkyl substituted with 1-3 R 59 ;  
   R 57  is selected from the group: 
 pyridine substituted with 0-1 R 58 , phenyl substituted with 0-1 R 58 , and C 1 -C 3  alkyl substituted with 0-3 R 60 ;  
   R 58  is independently selected at each occurrence from the group: —F, COOH, and OH;    R 59  is independently selected at each occurrence from the group: COOH, OH, and NHC(═O)R 63 , provided that at least one R 59  is NH(C═O)R 63 ;    R 60  is independently selected at each occurrence from the group: COOH, OH, C(═O)NH 2 , and NHC(═O)R 63 ;    R 61  is independently selected at each occurrence from the group: H, and C 1 -C 3  alkyl;    R 63  is independently selected at each occurrence from the group: phenyl substituted with 0-1 R 65 , and pyridine substituted with 0-1 R 65 ; and    R 65  is independently selected at each occurrence from the group: —Cl, —F, COOH, and OH.    
     
     
         30 . The compounds of  claim 29  that are:  
       
         
           
           
               
               
           
         
       
     
     
         31 . A method of treating disease in a mammal associated with infection and inflammation comprising administering to said mammal a therapeutically effective amount of a compound of claim  27 .